The appointment reflects the digital health company’s push to scale its commercial partnerships through channel-led growth as it continues a strategic review process.

April 15, 2026

DarioHealth Corp., the Nasdaq-listed digital health company, announced the appointment of John R. Palumbo to its board of directors as the company seeks to accelerate its commercial expansion through strategic partnerships across the healthcare ecosystem.

Palumbo brings more than four decades of healthcare leadership experience spanning both early-stage companies and Fortune 100 enterprises. His career includes senior roles at AmerisourceBergen, now known as Cencora, where he oversaw the provider business unit and grew consulting and technology capabilities into a multibillion-dollar platform serving health systems nationally. He also served as chief operating officer of Allscripts Healthcare Solutions, now Veradigm, and held leadership positions at Shared Medical Systems, which was later acquired by Siemens.

CEO Erez Raphael characterized the appointment as strategically intentional, noting that the company is transitioning from proving the strength of its distribution model to scaling it efficiently through channel partnerships. Raphael indicated that Palumbo’s extensive industry relationships with senior decision-makers across the payer, provider, and health services landscape would directly support the company’s growth trajectory. He also expressed growing confidence that the market will eventually recognize the full value the company has built.

Palumbo has guided organizations through transformative growth phases, including supporting two companies through initial public offerings and leading large-scale operational and commercial transformations. His experience is seen as particularly relevant to DarioHealth’s evolution toward a more capital-efficient, partner-driven go-to-market strategy.

Palumbo himself described DarioHealth as being at a compelling inflection point, noting that the company has built a differentiated and integrated solution with strong engagement metrics and proven clinical and economic outcomes. He said the key opportunity now lies in scaling that value through the right commercial channels.

The new board member is actively engaged in the broader digital health ecosystem, currently serving on the boards of PM Pediatrics Management Group, Lucid Diagnostics, ivWatch, and Qless. He also chairs the advisory board of Brado Cuneo Nollau, an AI-driven engagement platform serving health systems.

The appointment comes at a pivotal moment for DarioHealth. As previously reported, the company tripled its employer client base to 167 accounts in fiscal 2025 while cutting operating expenses by more than $21 million, even as revenue declined to $22.4 million from $27 million in the prior year. The company also launched AI-powered tools including DarioIQ, refinanced its debt through a new Callodine credit facility, and initiated a comprehensive strategic review in September 2025 following multiple unsolicited inbound expressions of interest.